CORE--CLINICAL PHARMACOLOGY

这个共享资源的存在是为了支持 临床研究协议，并使实验室翻译 项目进入临床试验。我们将监测药代动力学， 新药或组合在临床前和 临床水平。我们的作用，与参与 实验室，也将扩大调查和了解 某种药物或药物团成功或失败的原因， 分子目标的水平。我们将进行必要的分析 系统或修改现有的方法，特别是新的实验 毒品这一共享资源还提供了科学的联系， 基础研究和临床竞技场。这种相互作用允许 临床研究者开发研究，否则可能不会 可能所有的临床建议都与 共享资源总监和精确的科学问题被纳入 在最终版本的协议中。正如我们过去所做的那样， 优先支持I期和II期临床试验 从这个癌症中心概述的科学项目中发展出来的 提议

The existence of this Shared Resource is to support the implementation of clinical research protocols and to enable the translation of laboratory projects into clinical trials. We will monitor pharmacokinetics and pharmacodynamics of new drugs or combinations at both the preclinical and clinical level. Our role, in collaboration with the participating laboratories, will also be extended to investigate and understand the reasons for the success or failure of a certain drug or drug regiment at the level of the molecular target. We will develop necessary analytical systems or modify existing methods particularly for new experimental drugs. This Shared Resource also provides a scientific connections between basic research and the clinical arena. This interactions allows the clinical investigators to develop studies that otherwise might not be possible. All of the clinical proposals are extensively discussed with the Shared Resource director and precise scientific questions are incorporated in the final version of the protocols. As we have done in the past, priority support will be given to Phase I and Phase II clinical trials developed from the scientific programs outlined in this Cancer Center proposal.